HTG Molecular Diagnostics (NASDAQ: HTGM)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.810 | -0.1000 | ||||
REV | 2.150M | 1.184M | -966.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of HTG Molecular Diagnostics (NASDAQ: HTGM) through any online brokerage.
Other companies in HTG Molecular Diagnostics’s space includes: Pear Therapeutics (NASDAQ:PEAR), Better Therapeutics (NASDAQ:BTTX), UpHealth (NYSE:UPH), CareCloud (NASDAQ:MTBC) and Renalytix (NASDAQ:RNLX).
The latest price target for HTG Molecular Diagnostics (NASDAQ: HTGM) was reported by HC Wainwright & Co. on Monday, May 16, 2022. The analyst firm set a price target for 3.00 expecting HTGM to rise to within 12 months (a possible 177.78% upside). 4 analyst firms have reported ratings in the last year.
The stock price for HTG Molecular Diagnostics (NASDAQ: HTGM) is $1.08 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for HTG Molecular Diagnostics.
HTG Molecular Diagnostics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for HTG Molecular Diagnostics.
HTG Molecular Diagnostics is in the Health Care sector and Health Care Technology industry. They are listed on the NASDAQ.